What is the recommended treatment for Moraxella infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Moraxella Infections

Amoxicillin-clavulanate is the recommended first-line treatment for Moraxella infections due to widespread beta-lactamase production in these organisms. 1, 2

Microbiology and Clinical Significance

  • Moraxella catarrhalis (formerly Branhamella catarrhalis) is a gram-negative coccus that commonly causes respiratory tract infections 3
  • Most strains (>90%) produce beta-lactamase, making them resistant to penicillin, ampicillin, and amoxicillin 2
  • Moraxella is a common pathogen in acute otitis media in children (15-20% of cases) and acute exacerbations of COPD in adults 3

First-Line Treatment Options

  • Amoxicillin-clavulanate (875/125 mg twice daily for adults) is the preferred agent for Moraxella infections due to its effectiveness against beta-lactamase-producing strains 1, 4
  • For respiratory infections involving Moraxella catarrhalis, a 5-day course is typically sufficient for uncomplicated cases 4
  • In children, amoxicillin-clavulanate dosed at 25 mg/kg/day of the amoxicillin component in 2 divided doses is recommended 4

Alternative Treatment Options

  • Respiratory fluoroquinolones (levofloxacin 750 mg daily) are effective against Moraxella and can be used in patients with penicillin allergy 5, 4
  • Doxycycline (100 mg twice daily) provides good coverage for Moraxella infections and is a suitable alternative 4
  • Cephalosporins such as cefuroxime-axetil, cefpodoxime-proxetil, or cefixime are effective against beta-lactamase-producing Moraxella 4
  • Azithromycin (500 mg on day 1, then 250 mg for 4 days) can be used, particularly in cases of cat scratch disease where Moraxella may be a consideration 4, 6

Treatment Based on Infection Site

Respiratory Tract Infections

  • For acute exacerbations of COPD involving Moraxella, limit antibiotic treatment duration to 5 days 4
  • For community-acquired pneumonia with Moraxella, levofloxacin (750 mg daily) or amoxicillin-clavulanate are effective options 5, 4
  • In sinusitis caused by Moraxella, amoxicillin-clavulanate is recommended for patients with persistent symptoms for more than 10 days 4

Otitis Media

  • For acute otitis media caused by Moraxella in children, amoxicillin-clavulanate is the preferred agent 4, 6
  • Treatment duration is 8-10 days for children under 2 years and 5 days for older children 4

Skin and Soft Tissue Infections

  • For skin and soft tissue infections involving Moraxella, amoxicillin-clavulanate is effective 1, 4
  • For more severe infections, parenteral therapy may be necessary 4

Special Considerations

  • Immunocompromised patients: Moraxella can cause bacteremic pneumonia in immunosuppressed patients, requiring prompt and aggressive treatment 7
  • Ocular infections: Moraxella species rarely cause keratitis but can superinfect existing corneal lesions; fluoroquinolones like ciprofloxacin are effective 8
  • Nosocomial infections: Increasing documentation of nosocomial transmission requires attention to infection control measures 2

Common Pitfalls to Avoid

  • Misidentification: Moraxella resembles commensal Neisseria species in culture and may be overlooked in respiratory samples 3
  • Inappropriate antibiotic selection: Using penicillin, ampicillin, or amoxicillin alone is ineffective due to beta-lactamase production 2
  • Inadequate duration: While short courses (5 days) are typically sufficient for uncomplicated infections, more severe cases may require longer treatment 4
  • Failure to recognize resistance: Always consider local resistance patterns when selecting empiric therapy 4

By following these evidence-based recommendations, clinicians can effectively manage Moraxella infections while practicing antimicrobial stewardship.

References

Research

Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1998

Research

Moraxella catarrhalis, a human respiratory tract pathogen.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Moraxella catarrhalis bacteremic pneumonia in adults: two cases and review of the literature.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1992

Research

Moraxella nonliquefaciens superinfecting herpes simplex keratitis.

European journal of ophthalmology, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.